{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:35:01Z","timestamp":1793180101752,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.omtm.2024.101271","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:11:05Z","timestamp":1716243065000},"page":"101271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Stuart","family":"Ellison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Buckland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Learmonth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spandan","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Roman-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Bonafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Holley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Smythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Bigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101271_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjh.17269","article-title":"Gene therapy for primary immunodeficiencies","volume":"193","author":"Fox","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2024.101271_bib2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14712598.2023.2192348","article-title":"Ex\u00a0vivo gene therapy for lysosomal storage disorders: future perspectives","volume":"23","author":"Poletto","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/v15030713","article-title":"Gene Therapy for \u03b2-Hemoglobinopathies: From Discovery to Clinical Trials","volume":"15","author":"Segura","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2024.101271_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2024.101271_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141762","article-title":"Ex-Vivo Autologous Stem Cell Gene Therapy Clinical Trial for Mucopolysaccharidosis Type IIIA: Trial in Progress - NCT04201405","volume":"136","author":"Kinsella","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101271_bib7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMe1802169","article-title":"Gene Therapy as a Curative Option for beta-Thalassemia","volume":"378","author":"Biffi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/d41587-019-00026-3","article-title":"First gene therapy for beta-thalassemia approved","volume":"37","author":"Harrison","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2024.101271_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex\u00a0vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib14","first-page":"207","article-title":"Novel approaches and mechanisms in hematopoietic stem cell gene therapy","volume":"17","author":"Bigger","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib15","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.21129.1","article-title":"Mobilized peripheral blood: an updated perspective","volume":"8","author":"Karpova","year":"2019","journal-title":"F1000Res."},{"key":"10.1016\/j.omtm.2024.101271_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fped.2019.00443","article-title":"Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives","volume":"7","author":"Staal","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.omtm.2024.101271_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2016.103","article-title":"The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy","volume":"27","author":"Bernardo","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41434-021-00261-x","article-title":"The transformative potential of HSC gene therapy as a genetic medicine","volume":"30","author":"Sagoo","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035787","article-title":"Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB","volume":"7","author":"Wilkinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101271_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2024.101271_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.omtm.2024.101271_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtm.2024.101271_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101127","article-title":"Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy","volume":"31","author":"Ellison","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib24","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/hum.2023.002","article-title":"Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease","volume":"35","author":"Mandolfo","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib26","series-title":"Cell Therapy: cGMP Facilities and Manufacturing","first-page":"339","article-title":"Indiana University Vector Production Facility (IUVPF)","author":"Bischof","year":"2022"},{"key":"10.1016\/j.omtm.2024.101271_bib27","first-page":"161","article-title":"Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument","volume":"1","author":"Panch","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.omtm.2024.101271_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2019.05.015","article-title":"Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application","volume":"14","author":"Schott","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41434-020-0150-z","article-title":"Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy","volume":"27","author":"Jang","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib31","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex\u00a0Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.omtm.2017.03.003","article-title":"Genetic Engineering and Manufacturing of Hematopoietic Stem Cells","volume":"5","author":"Wang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/106161299320488","article-title":"Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device","volume":"8","author":"Schumm","year":"1999","journal-title":"J.\u00a0Hematother."},{"key":"10.1016\/j.omtm.2024.101271_bib34","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/hum.2020.276","article-title":"Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47(phox)-Deficient Chronic Granulomatous Disease","volume":"32","author":"Schejtman","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib36","first-page":"6","article-title":"Interleukin-3 and ex\u00a0vivo maintenance of hematopoietic stem cells: facts and controversies","volume":"15","author":"Ivanovic","year":"2004","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.omtm.2024.101271_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107171","article-title":"Sustained biochemical engraftment and early clinical outcomes following autologous stem cell gene therapy for mucopolysaccharidosis type IIIA","volume":"138","author":"Jones","year":"2023","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101271_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtm.2019.04.001","article-title":"Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex\u00a0Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA","volume":"13","author":"Ellison","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","article-title":"Efficient Ex\u00a0Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy","volume":"8","author":"Zonari","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.omtm.2024.101271_bib40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtm.2024.101271_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","article-title":"Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency","volume":"9","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib42","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral Gene Therapy for Artemis-Deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101271_bib43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omtm.2022.07.015","article-title":"Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type I","volume":"26","author":"Mesa-Nunez","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101271_bib44","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14712598.2022.2101361","article-title":"Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies","volume":"22","author":"Li","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/mt.2013.265","article-title":"Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency","volume":"22","author":"Carbonaro","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101271_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/bc900382q","article-title":"Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase","volume":"21","author":"Lu","year":"2010","journal-title":"Bioconjug. Chem."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T07:05:37Z","timestamp":1726383937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2329050124000871"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101271","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101271"}}